Robert Brennan: Non-Invasive Metabolomic Test for Embryo Selection
Robert Brennan, Chief Executive Officer at Embryomic, shared a post by Embryomic on LinkedIn:
“Sharing Week 2 of our five-part preprint series on PMT-BC, Embryomic’s non-invasive metabolomic test for embryo selection.
This paper asks a key question in IVF: what defines success — implantation or viability?
By analysing spent culture media, PMT-BC helps distinguish these outcomes and complements morphology and PGT-A to improve viable pregnancy rates.”
Quoting Embryomic’s post:
“Week 2 of our five-part PMT-BC preprint series is now live.
This release focuses on one of the most important questions in IVF: how do we define success in embryo selection – implantation or viability?
Implantation: whether the embryo attaches to the endometrium
Viability: whether implantation leads to a sustained pregnancy
By analysing metabolomic profiles from spent culture media, PMT-BC helps to distinguish these outcomes, providing a more clinically relevant measure of embryo competence.
This work lays the foundation for PMT-BC to complement morphology and PGT-A, supporting clearer, evidence-based decisions for embryo transfer.
Read the Week 2 preprint here.”
-
Mar 21, 2026, 19:55Rebecca Mallick: Fertility Must Become Standard in Endometriosis Care
-
Mar 21, 2026, 19:48Kendra Batchelder: The Momentum Behind Women’s Health Innovation
-
Mar 21, 2026, 19:44COVID-19 Vaccination During Pregnancy in 2026 – Weence Health Content Services
-
Mar 21, 2026, 19:37Endometriosis and the Endocannabinoid System – ANTG
-
Mar 21, 2026, 19:35Corina Carpenter: A Guide to Clinical Trial Compensation in San Antonio
-
Mar 21, 2026, 19:31The Signals Behind PCOS – PCOS Awareness Association
-
Mar 21, 2026, 19:26Paternal Impact on Embryo Morphokinetics and ART Success – RBMO
-
Mar 21, 2026, 19:19Christopher Robinson: Maternal Fetal Pharmacokinetics of Azithromycin in Preterm Premature Rupture of Membranes
-
Mar 21, 2026, 19:13Lori Brumat: Why Women’s Health Should Matter to Everyone Right Now
